Drug Profile

SLS 004

Alternative Names: Gene therapy programme - Duke University/Seelos Therapeutics; LV-dCas9-DNMT3A; SLS-004

Latest Information Update: 17 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Duke University
Developer Duke University; Seelos Therapeutics
Class Antidementias; Antiparkinsonians; Gene therapies
Mechanism of Action Alpha-synuclein expression inhibitors; Gene expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Dec 2022 Preclinical trials in Parkinson's disease still ongoing in USA (Parenteral)
15 Dec 2022 Preliminary pharmacodynamics data from preclinical studies in Parkinson's disease released by Seelos Therapeutics
15 Dec 2022 Seelos plans to advance the study of SLS 004 in Parkinson's disease

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com